Marco Investment Management LLC Purchases 930 Shares of Exact Sciences Co. (NASDAQ:EXAS)

Marco Investment Management LLC boosted its position in shares of Exact Sciences Co. (NASDAQ:EXAS) by 1.1% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 83,285 shares of the medical research company’s stock after acquiring an additional 930 shares during the quarter. Marco Investment Management LLC’s holdings in Exact Sciences were worth $6,161,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in EXAS. Wolff Wiese Magana LLC raised its position in shares of Exact Sciences by 459.5% in the fourth quarter. Wolff Wiese Magana LLC now owns 414 shares of the medical research company’s stock valued at $31,000 after purchasing an additional 340 shares during the period. BluePath Capital Management LLC bought a new position in shares of Exact Sciences in the third quarter valued at about $33,000. Cullen Frost Bankers Inc. raised its position in shares of Exact Sciences by 40.0% in the third quarter. Cullen Frost Bankers Inc. now owns 700 shares of the medical research company’s stock valued at $48,000 after purchasing an additional 200 shares during the period. Valley National Advisers Inc. raised its position in shares of Exact Sciences by 29.5% in the third quarter. Valley National Advisers Inc. now owns 773 shares of the medical research company’s stock valued at $53,000 after purchasing an additional 176 shares during the period. Finally, Milestone Investment Advisors LLC bought a new position in shares of Exact Sciences in the third quarter valued at about $57,000. 88.82% of the stock is owned by institutional investors.

Exact Sciences Trading Up 0.1 %

Exact Sciences stock traded up $0.06 during mid-day trading on Friday, hitting $58.85. 2,019,062 shares of the stock were exchanged, compared to its average volume of 2,963,292. The company has a quick ratio of 2.07, a current ratio of 2.32 and a debt-to-equity ratio of 0.74. Exact Sciences Co. has a 12 month low of $56.05 and a 12 month high of $100.77. The firm’s fifty day simple moving average is $63.44 and its two-hundred day simple moving average is $64.93. The stock has a market capitalization of $10.68 billion, a price-to-earnings ratio of -51.62 and a beta of 1.25.

Exact Sciences (NASDAQ:EXAS) last released its quarterly earnings data on Wednesday, February 21st. The medical research company reported ($0.27) earnings per share for the quarter, beating the consensus estimate of ($0.53) by $0.26. The company had revenue of $646.89 million during the quarter, compared to analyst estimates of $638.83 million. Exact Sciences had a negative net margin of 8.17% and a negative return on equity of 6.60%. Exact Sciences’s revenue for the quarter was up 17.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.72) EPS. Analysts forecast that Exact Sciences Co. will post -0.86 EPS for the current year.

Wall Street Analyst Weigh In

EXAS has been the topic of a number of recent research reports. Canaccord Genuity Group lowered their price target on shares of Exact Sciences from $100.00 to $90.00 and set a “buy” rating on the stock in a research report on Thursday, February 22nd. Citigroup reaffirmed a “buy” rating and set a $100.00 price target on shares of Exact Sciences in a research report on Wednesday, April 3rd. William Blair reaffirmed an “outperform” rating on shares of Exact Sciences in a research report on Thursday, February 22nd. TheStreet lowered shares of Exact Sciences from a “c-” rating to a “d+” rating in a research report on Monday, February 26th. Finally, Benchmark upgraded shares of Exact Sciences from a “hold” rating to a “buy” rating and set a $91.00 price objective on the stock in a research note on Tuesday, January 2nd. Three research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. According to data from MarketBeat, Exact Sciences presently has an average rating of “Moderate Buy” and a consensus price target of $97.44.

Insider Activity

In related news, CEO Kevin T. Conroy sold 14,791 shares of Exact Sciences stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $61.43, for a total value of $908,611.13. Following the completion of the sale, the chief executive officer now owns 1,224,357 shares of the company’s stock, valued at approximately $75,212,250.51. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In related news, General Counsel James Herriott sold 415 shares of Exact Sciences stock in a transaction on Wednesday, February 21st. The shares were sold at an average price of $61.50, for a total value of $25,522.50. Following the completion of the sale, the general counsel now owns 6,943 shares of the company’s stock, valued at approximately $426,994.50. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO Kevin T. Conroy sold 14,791 shares of Exact Sciences stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $61.43, for a total transaction of $908,611.13. Following the completion of the sale, the chief executive officer now directly owns 1,224,357 shares of the company’s stock, valued at approximately $75,212,250.51. The disclosure for this sale can be found here. Insiders sold 69,113 shares of company stock worth $4,165,273 in the last quarter. 1.30% of the stock is owned by corporate insiders.

About Exact Sciences

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.